CDC/NIH VIRAZOLE HANTAVIRUS STUDY HAS ENROLLED 130-140 PATIENTS
Executive Summary
CDC/NIH VIRAZOLE HANTAVIRUS STUDY HAS ENROLLED 130-140 PATIENTS, close to the target enrollment for the study of 150, Centers for Disease Control & Prevention Drug Service Head John Becher said June 30. The open-label trial began enrollment in June 1993, shortly after the outbreak of the virus in May, and is being administered by the National Institutes of Health and CDC in the "Four Corners" area of Colorado, Arizona, New Mexico and Utah. The trial protocol was designed by FDA. CDC is purchasing the study medication, a parenteral formulation of Virazole (ribavirin) from ICN's Viratek subsidiary.